<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03169881</url>
  </required_header>
  <id_info>
    <org_study_id>NICHD-NRN-0058</org_study_id>
    <nct_id>NCT03169881</nct_id>
  </id_info>
  <brief_title>Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants</brief_title>
  <acronym>Darbe</acronym>
  <official_title>Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NICHD Neonatal Research Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>NICHD Neonatal Research Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Hypothesis: Preterm infants administered weekly Darbe during the neonatal period will
      have improved neurocognitive outcome at 22-26 months compared to placebo
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Advances in neonatal care have led to significant improvements in the survival of the nearly
      60,000 very low birth weight (VLBW) infants born each year in the U.S. Improving
      neurodevelopmental outcomes for these preterm infants continues to be a major goal for
      neonatal care providers. A subset of these infants sustain a grade 3 or 4 intraventricular
      hemorrhage (IVH) resulting in an increase in the incidence of developmental delay. Moreover,
      almost one third of preterm infants with normal head ultrasounds also develop cognitive
      delay. Although a variety of neuroprotective treatment strategies have been evaluated, no
      specific treatment has been identified to reduce or prevent brain injury in these most
      vulnerable preterm infants.

      A potential neuroprotective therapy involves administering erythropoiesis stimulating agents
      (ESAs) such as erythropoietin (Epo) and Darbepoetin (Darbe, a longer acting ESA). In addition
      to stimulating erythropoiesis, ESAs have been shown to be protective in the developing brain
      in animal models, making it possibly beneficial for very premature infants who are at risk
      for intraventricular hemorrhage, hypoxic-ischemic injury, and developmental delay. The
      neuroprotective mechanisms of ESAs include increased neurogenesis, decreased neuronal
      susceptibility to glutamate toxicity, decreased neuronal apoptosis, decreased inflammation,
      decreased nitric oxide-mediated injury, increased antioxidant response, decreased axonal
      degeneration, and increased protective effects on glia. This is a randomized, masked, placebo
      controlled clinical study in which enrolled infants will receive weekly Darbe or placebo
      (sham) dosing.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 20, 2017</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, masked, placebo-controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Primary providers and bedside caregivers will be blinded to randomization group. If the dose will be administered IV, the study drug will be administered slow IV push by the bedside nurse. If the dose will be administered subcutaneously, the study drug will be brought to the bedside in a closed container, and injections will be shielded behind screens and out of earshot from caregivers and parents. An adhesive bandage (or 2x2 gauze) will be placed over the true and sham injection sites and either taped or held in place until no evidence of the injection is visible. The parents, medical providers, data collection staff and neurodevelopmental follow up personnel will be masked to the treatment arm.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Composite cognitive score on Bayley Scale of Infant Development III</measure>
    <time_frame>Birth to 26 months corrected age</time_frame>
    <description>The primary outcome is the Bayley III cognitive score. Deaths will be assigned a score of 54.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>Birth to 26 months corrected age</time_frame>
    <description>Death includes any mortality prior to follow-up at 22-26 months of age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral Palsy</measure>
    <time_frame>Follow-up at 26 months corrected age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Hospital Stay</measure>
    <time_frame>Birth to 26 months corrected age</time_frame>
    <description>Days in hospital following birth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of transfusions</measure>
    <time_frame>Birth to 35 completed weeks gestational age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematocrit</measure>
    <time_frame>Birth to 35 completed weeks gestational age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red cell mass</measure>
    <time_frame>Birth to 35 completed weeks gestational age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of transfusions</measure>
    <time_frame>Birth to 35 completed weeks gestational age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurodevelopmental impairment (NDI)</measure>
    <time_frame>26 months corrected age</time_frame>
    <description>Severe NDI will be defined by any of the following: a BSID III cognitive score &lt; 70, Gross Motor Functional (GMF) Level of 3-5, blindness (&lt;20/200 vision) or profound hearing loss (inability to understand commands despite amplification); moderate NDI will be defined as a BSID III cognitive score 70-84 and either a GMF level of 2 or a hearing deficit requiring amplification to understand commands or unilateral blindness; mild NDI will be defined by a cognitive score 70-84, or a cognitive score ≥ 85 and any of the following: presence of a GMF level 1 or hearing loss not requiring amplification. Normal (no NDI) will be defined by a cognitive score ≥ 85 and absence of any neurosensory deficits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seizures</measure>
    <time_frame>Up to 120 days of life</time_frame>
    <description>Documented seizures during hospital course</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thromboses</measure>
    <time_frame>Up to 120 days of life</time_frame>
    <description>Documented thromboses during hospital course</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypertension</measure>
    <time_frame>Up to 120 days of life</time_frame>
    <description>Documented hypertension during hospital course</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra-cranial Hemorrhage (ICH)</measure>
    <time_frame>Up to 120 days of life</time_frame>
    <description>Documented ICH during hospital course</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Necrotizing Enterocolitis (NEC) requiring surgery</measure>
    <time_frame>Up to 120 days of life</time_frame>
    <description>Documented NEC requiring surgery during hospital course</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bronchopulmonary dysplasia (BPD)</measure>
    <time_frame>Up to 120 days of life</time_frame>
    <description>Documented BPD during hospital course</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinopathy of prematurity (ROP) requiring intervention</measure>
    <time_frame>Up to 120 days of life</time_frame>
    <description>Documented ROP requiring intervention (to include but not limited to laser, cryotherapy, scleral buckle, vitrectomy, avastin Injection) during hospital course</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Culture positive sepsis</measure>
    <time_frame>Up to 120 days of life</time_frame>
    <description>Documented culture positive sepsis during hospital course</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">650</enrollment>
  <condition>Neurocognitive</condition>
  <condition>Neuroprotective</condition>
  <condition>Neonatal</condition>
  <condition>Neurodevelopmental Impairment</condition>
  <arm_group>
    <arm_group_label>Darbepoetin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Darbepoetin 10 micrograms/kg/once every week (IV or SC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Equal volume normal saline for IV administration, or sham dosing</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darbepoetin</intervention_name>
    <description>Darbepoetin 10 micrograms/kg/once every week (IV or SC). Infants will be treated until 35 completed weeks gestation, discharge, or transfer to another hospital.</description>
    <arm_group_label>Darbepoetin</arm_group_label>
    <other_name>Darbe</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>normal saline for IV administration, or sham dosing. Infants will be treated until 35 completed weeks gestation, discharge, or transfer to another hospital.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>normal saline for IV administration, or sham dosing</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inborn and outborn preterm infants

          -  23 0/7-28 6/7 weeks gestation

          -  ≤24 hours postnatal age

        Exclusion Criteria:

          -  Hematocrit &gt; 60%

          -  Infants with known congenital or chromosomal anomalies, including congenital heart
             disease and known brain anomalies

          -  Hemorrhagic or hemolytic disease

          -  EEG- confirmed seizures

          -  Congenital thrombotic disease

          -  Systolic blood pressures &gt;100 mm Hg while not on pressor support

          -  Receiving Epo or Darbe clinically, or planning to receive Epo or Darbe during
             hospitalization

          -  Infants in whom no aggressive therapy is planned

          -  Family will NOT be available for follow-up at 22-26 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>23 Weeks</minimum_age>
    <maximum_age>28 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robin Ohls, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Mexico</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robin Ohls, MD</last_name>
    <phone>505-272-0180</phone>
    <email>rohls@salud.unm.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rosemary D Higgins, MD</last_name>
    <phone>301-435-5575</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Waldemar A. Carlo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Waldemar A. Carlo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Krisa P. Van Meurs, MD</last_name>
    </contact>
    <investigator>
      <last_name>Krisa P. Van Meurs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Carlton, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Edward F. Bell, MD</last_name>
    </contact>
    <investigator>
      <last_name>Edward F. Bell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin Ohls, MD</last_name>
      <phone>505-272-0180</phone>
    </contact>
    <investigator>
      <last_name>Kristi L. Watterberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carl T D'Angio, MD</last_name>
    </contact>
    <investigator>
      <last_name>Carl T D'Angio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>RTI International</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>C. Michael Cotten, MD</last_name>
    </contact>
    <investigator>
      <last_name>C. Michael Cotten, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenda Poindiexter, MD</last_name>
    </contact>
    <investigator>
      <last_name>Brenda Poindexter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University, Rainbow Babies and Children's Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michele C. Walsh, MD MS</last_name>
    </contact>
    <investigator>
      <last_name>Michele C. Walsh, MD MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Institute at Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pablo Sanchez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pablo Sanchez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univeristy of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric C Eichenwald, MD</last_name>
    </contact>
    <investigator>
      <last_name>Eric C Eichenwald, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brown University - Women and Infants Hospital of Rhode Island</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Abbot R. Laptook, MD</last_name>
    </contact>
    <investigator>
      <last_name>Abbot R Laptook, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Myra Myckoff, MD</last_name>
    </contact>
    <investigator>
      <last_name>Myra Wyckoff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jon Tyson</last_name>
    </contact>
    <investigator>
      <last_name>Jon Tyson, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bradley Yoder, MD</last_name>
    </contact>
    <investigator>
      <last_name>Bradley Yoder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2017</study_first_submitted>
  <study_first_submitted_qc>May 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2017</study_first_posted>
  <last_update_submitted>October 31, 2017</last_update_submitted>
  <last_update_submitted_qc>October 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darbepoetin alfa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>NIH has had a long-standing policy to share and make available to the public the results and accomplishments of the activities that it funds. The NRN plans to share de-identified data after final publication in an NIH supported data repository such as the NICHD Data and Specimen Hub (https://dash.nichd.nih.gov) or NHLBI BIOLINCC (https://biolincc.nhlbi.nih.gov/home/).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

